FindTrial
Sign In

Analysis of Long-Term Outcomes and Risk Factors for Peripheral Artery Disease Using a Multi-Center Clinical Database

Development and Application of a REDCap-Based Multi-Center Clinical Database for Peripheral Artery Disease - REDCap-PAD Multicenter Database Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116024
Enrollment
Unknown
Registered
2026-01-04
Start date
2026-01-10
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Arterial Disease

Interventions

Aortic Aneurysm group:None
Aortic Dissection group:None
Carotid Artery Stenosis group:None
Visceral Artery Aneurysm group:None
Lower Limb Ischemia group:None

Sponsors

School of Public Health, Xi’an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Aged >=18 years and <=90 years, regardless of gender. 2.Clearly diagnosed with peripheral arterial diseases such as lower extremity arteriosclerosis obliterans, thromboangiitis obliterans, diabetic peripheral vascular disease, carotid artery stenosis, or renal artery stenosis. 3.Ankle-brachial index (ABI) < 0.9. 4.Presence of at least one of the following symptoms of distal limb ischemia: numbness, rest pain, intermittent claudication, or ischemic ulcer. 5.Peripheral arterial disease confirmed by imaging examinations (ultrasound, CT, or DSA). 6.The subject has signed the informed consent form for this trial.

Exclusion criteria

Exclusion criteria: 1.Patients with severe primary diseases of the cardiovascular, cerebrovascular, pulmonary, hepatic, renal, or hematopoietic systems, or psychiatric disorders. 2.Patients with concurrent inflammatory or neoplastic diseases. 3.Patients who have participated in other drug or medical device clinical trials that may interfere with this trial within the past three months. 4.Patients with allergic constitution or relevant drug allergies. 5.Women who are pregnant or breastfeeding. 6.Patients who are unable or unwilling to participate in this trial.

Design outcomes

Primary

MeasureTime frame
all-cause mortality;Target vessel-related mortality;Incidence of stroke;Lower limb amputation rate;Stent migration or fracture;—

Secondary

MeasureTime frame
Target vessel revascularization rate;Change in aneurysm diameter;Endoleak after EVAR/TVAR;Lower limb ankle-brachial index (ABI);SF-36 Quality of Life Questionnaire;Quality of Life (QoL) score;—

Countries

China

Contacts

Public ContactZOU Junjie

The First Affiliated Hospital of Nanjing Medical University

15950360001@163.com+86 159 5036 0001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026